Afolabi, Muhammed O; Tiono, Alfred B; Adetifa, Uche J; Yaro, Jean Baptiste; Drammeh, Abdoulie; Nébié, Issa; Bliss, Carly; Hodgson, Susanne H; Anagnostou, Nicholas A; Sanou, Guillaume S; +22 more... Jagne, Ya Jankey; Ouedraogo, Oumarou; Tamara, Casimir; Ouedraogo, Nicolas; Ouedraogo, Mirielle; Njie-Jobe, Jainaba; Diarra, Amidou; Duncan, Christopher Ja; Cortese, Riccardo; Nicosia, Alfredo; Roberts, Rachel; Viebig, Nicola K; Leroy, Odile; Lawrie, Alison M; Flanagan, Katie L; Kampman, Beate; Bejon, Philip; Imoukhuede, Egeruan B; Ewer, Katie J; Hill, Adrian Vs; Bojang, Kalifa; Sirima, Sodiomon B; (2016) Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular therapy, 24 (8). pp. 1470-1477. ISSN 1525-0016 DOI: https://doi.org/10.1038/mt.2016.83
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.
Item Type | Article |
---|---|
Faculty and Department |
Faculty of Infectious and Tropical Diseases > Dept of Disease Control MRC Gambia > GM-Disease Control and Elimination Theme |
PubMed ID | 27109630 |
ISI | 383280900018 |
Related URLs |
Download
Filename: Safety and Immunogenicity of_GOLD VoR.pdf
Licence: Creative Commons: Attribution 3.0
Download